$10 Billion Deal, page-8641

You may want to read these?

https://stocknessmonster.com/announcements/bit.asx-2A1248447/
https://stocknessmonster.com/announcements/bit.asx-2A1286464/
https://stocknessmonster.com/announcements/bit.asx-2A1309021/
The proposed Australian trial (BIT225‐011) will include people who have been on approved
anti‐HIV‐1 treatment (ART) for an extended period, with well‐controlled HIV‐1 infection, but who have not achieved full immune reconstitution. It has been estimated that up to 40% of HIV‐infected people do not achieve immune reconstitution despite virus levels below the level of detection. This population is at an increased risk of clinical progression to AIDS and non‐AIDS events and has higher rates of mortality than HIV‐infected individuals with adequate immune reconstitution. BIT225 will be added to this group’s ART treatment for a period of three months. The endpoints will include measurements of improved immune function and markers that link to immune reconstitution.